Merck recommends rejection of TRC Capitals mini-tender offer
| PHPIX Fund | USD 27.85 0.48 1.75% |
Slightly above 54% of Pharmaceuticals Ultrasector's investors are presently thinking to get in. The analysis of overall sentiment of trading Pharmaceuticals Ultrasector Profund mutual fund suggests that some investors are interested at this time. Pharmaceuticals Ultrasector's investing sentiment can be driven by a variety of factors including economic data, Pharmaceuticals Ultrasector's earnings reports, geopolitical events, and overall market trends.
Pharmaceuticals |
Merck advises shareholders to reject TRC Capitals mini-tender offer to purchase shares below market price.
Read at seekingalpha.com
 |
Pharmaceuticals Ultrasector Fundamental Analysis
We analyze Pharmaceuticals Ultrasector's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmaceuticals Ultrasector using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmaceuticals Ultrasector based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Pharmaceuticals Ultrasector is currently under evaluation in net asset among similar funds. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Pharmaceuticals Ultrasector Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pharmaceuticals Ultrasector mutual fund to make a market-neutral strategy. Peer analysis of Pharmaceuticals Ultrasector could also be used in its relative valuation, which is a method of valuing Pharmaceuticals Ultrasector by comparing valuation metrics with similar companies.
Peers
Pharmaceuticals Ultrasector Related Equities
| LGPSX | Profunds Large | 0.87 | ||||
| LGPIX | Large Cap | 0.85 | ||||
| UIPSX | Ultrashort Mid-cap | 0.71 | ||||
| UIPIX | Ultrashort Mid-cap | 0.69 | ||||
| BRPIX | Bear Profund | 0.44 | ||||
| BRPSX | Bear Profund | 0.39 | ||||
| SRPSX | Short Real | 0.61 | ||||
| SRPIX | Short Real | 0.65 | ||||
| TEPIX | Technology Ultrasector | 2.08 | ||||
| TEPSX | Technology Ultrasector | 2.08 |
Other Information on Investing in Pharmaceuticals Mutual Fund
Pharmaceuticals Ultrasector financial ratios help investors to determine whether Pharmaceuticals Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmaceuticals with respect to the benefits of owning Pharmaceuticals Ultrasector security.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |